June 2017<\/p>\n
Selected items from the News and Latest Additions sections of www.palliativedrugs.com<\/a>, the world\u2019s leading palliative care website with over 30,000 members from 169 Countries.<\/strong><\/p>\n Safety updates<\/strong><\/p>\n FDA restricts codeine and tramadol in children and adolescents<\/strong> For more information, click here<\/a>.<\/p>\n Editor\u2019s note: The restrictions for codeine reflect those issued in the UK by the MHRA in April 2015 (for cough<\/a>) and July 2013 (for pain<\/a>). The MHRA have not specifically highlighted any restrictions in <\/p>\n Drug updates<\/strong><\/p>\n Acetylcysteine oral powder launched in UK<\/strong> Nystatin dose changes in the BNF and SPC<\/strong> Editor\u2019s note: PCF has always recommended a higher dose of nystatin oral suspension 100,000units\/mL of 5mL PO q.d.s. for oral candidosis. Nystatin is a topical treatment and few people have the oral dexterity to cover the relevant areas with just 1mL, i.e. it is an issue of volume and not the dose itself. The authorized dose in the USA is 4\u22126mL q.d.s.<\/p>\n Fentanyl lozenges (Actiq) risk minimization guides<\/strong> Prescription guide<\/a> <\/p>\n Latest additions<\/strong><\/p>\n Restructured and updated PCF Part 2 live on the website<\/strong> For full details, see the link below. We will now be focusing on completing updates to Part 1 monographs which will be subsequently added to the website. Follow us on twitter@palliativedrugs for the latest updates.<\/p>\n <\/p>\n Survey results<\/strong><\/p>\n Results are available from our latest survey, \u2018SSRIs for pruritus \u2013 Do you use them?\u2019. For more information, click here<\/a>.<\/p>\n <\/p>\n Prepared by Sarah Charlesworth and Andrew Wilcock.<\/p>\n","protected":false},"excerpt":{"rendered":" June 2017 Selected items from the News and Latest Additions sections of www.palliativedrugs.com, the world\u2019s leading palliative care website with over 30,000 members from 169 Countries. Safety updates FDA restricts codeine and tramadol in children and adolescents As part of an on-going safety review, the FDA have further restricted the use of codeine and tramadol: […]<\/p>\n
\nAs part of an on-going safety review, the FDA have further restricted the use of codeine and tramadol:<\/p>\n\n
\nthe UK for tramadol, which is unauthorized for use in children <12 years.<\/p>\n
\nA new oral acetylcysteine powder is now available in the UK, authorized as a mucolytic adjuvant for respiratory disorders associated with thick, viscous, mucus hypersecretion. The dose is 200mg
\n(1 sachet, dissolved in a little water) three times a day. The cost for 28 days@ 1 sachet t.d.s. = \u00a3315. For more information, click here<\/a>.<\/p>\n
\nThe dose for oral candidosis in the BNF and all the SPCs for nystatin 100,000units\/mL oral suspension, is now 1mL PO q.d.s.. There has been recent confusion over the authorized dose with generic and proprietary SPCs including differing dose schedules. The dose in the Nystan (Sqibb) SPC was increased in September 2016 from 1mL to 4\u22126mL q.d.s., but has now been changed back to 1mL q.d.s. This was after further discussion with the MHRA who re-assessed the evidence and did not find it robust enough to support the dose increase. For more information, click here<\/a>.<\/p>\n
\nAs part of the terms of the Marketing Authorization for Actiq (fentanyl lozenges; Teva), the company have published the following educational guides to minimize risk of misuse\/dependence, abuse, medication errors, drug diversion, accidental exposure, overdose, off-label use, respiratory depression and dental decay in patients on opioids.<\/p>\n
\nPatient guide<\/a>
\nPatient treatment diary<\/a><\/p>\n
\nWe are delighted to announce the launch of the new format for Part 2 of PCF on the www.palliativedrugs.com<\/a> website in anticipation of PCF6 print publication in late 2017. This work has been completed separately over the last 3 months. In addition, several updates to Part 1 monographs have also been completed. The changes include:<\/p>\n\n
\n
\nList of changes and restructure Jan-April 2017<\/a><\/p>\n